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Abstract 
Over 70% of head & neck squamous cell carcinoma (HNSCC) patients carry TP53 oncogenic mutations. 
Here we studied the role of specific tumor-derived mutant p53 proteins in the aberrant transcription of 
long non-coding (lnc) MIR205HG gene in head and neck cancer cells. 
Methods: To understand the role of lncMIR205HG, that we showed to be transcriptionally regulated by 
mutant p53 in HNSCC, we have employed siRNA and shRNA in CAL27 and FaDu HNSCC cell lines to 
suppress p53 gene expression in ChIP assays and RT-qPCR. We validated our findings in a cohort of 522 
HNSCC patients from The Cancer Genome Atlas Data Portal (TCGA). We further evaluated our results 
in 63 HNSCC tumor samples collected at our institute, 32 of which were characterized by mutated TP53 
(missense mutations) while 31 were characterized by wild-type TP53. 
Results: Maturation of pre-MIR205HG transcript produces two non-coding RNAs, lncMIR205HG and 
hsa-miR-205-5p. Down-regulation of lncMIR205HG expression significantly reduced cell proliferation, 
cell migration and clonogenic activity of head and neck cancer cells. Expression of MIR205HG was 
significantly increased in HNSCC with mutated TP53 when compared with matched non-tumoral tissues. 
Furthermore, MIR205HG expression levels were significantly higher in tumoral samples with mutant p53 
than in tumoral tissues expressing wild-type p53. Mechanistically, MIR205HG depletes endogenous 
miR-590-3p leading to increased cyclin B, cdk1, and YAP protein expression. 
Conclusions: Taken together, these findings identify a transcriptional and post-transcriptional molecular 
network that includes mutant p53 protein, lncMIR205HG, YAP, and other proliferation-related genes, 
which are enriched in HNSCC patients with poor prognosis. 
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Introduction 
Somatic missense mutations in TP53 gene occur 
in over half of all human cancers and may impact the 
residues involved in direct contact with DNA (DNA 
contact mutants) or substitute the amino acids 
required for proper p53 protein folding and structure 
(conformational mutants) [1, 2]. Mutations in the p53 
protein may not only disrupt its wild-type tumor- 
suppressing function but also confer new oncogenic 
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properties (GOF, gain-of-function) that provide a 
selective growth advantage to the tumor cells [3]. 
Mutant p53 (mutp53) proteins with GOF do not 
recognize specific wt-p53 consensus sequences in the 
target gene promoters but have been shown to 
interact with and aberrantly promote the activity of 
several transcription factors, such as NF-Y, SREBPs, 
E2F1-4, Ets-1, and YAP [4-9]. Furthermore, mutations 
in the TP53 gene are associated with poor clinical 
outcome in several human cancers including head 
and neck squamous cell carcinoma (HNSCC) [3, 10, 
11]. 
Long noncoding RNAs (lncRNAs) belong to a 
class of ncRNAs that are longer than 200 nucleotides 
[12, 13]. Several studies have shown that lncRNAs 
may act as important cis- or trans-regulators in 
various biological processes [14-16]. Mutations in 
lncRNAs or deregulation of their expression are 
associated with a wide range of diseases, especially 
cancers and neurodegenerative diseases, through 
diverse and poorly understood molecular 
mechanisms [12, 14]. A recurrent theme in lncRNA 
biology is their ability to function in the recruitment of 
protein factors for regulation of chromatin states [15]. 
Moreover, lncRNAs may suppress precursor mRNA 
splicing by depleting RNA-binding proteins and/or 
modulate translation by acting as decoys for 
microRNAs, thus releasing microRNA-mediated 
inhibition of target mRNA expression [16]. Finally, 
lncRNAs can influence protein localization and 
participate in the formation of protein complexes 
where they perform scaffolding functions [15-18].  
MicroRNAs (miRNAs) are 22-nucleotide-long 
non-coding RNAs (ncRNAs), which can modulate 
gene expression at the post-transcriptional level. 
Importantly, tumorigenesis has been linked to the 
deregulated expression of miRNAs, which could act 
either as tumor suppressors or oncogenes (oncomirs) 
and may also contribute to tumor metastasis [19-22]. 
miRNAs are therefore emerging as markers for 
diagnosis, staging, and treatment of cancer [19, 23, 24]. 
Wild-type p53 has been shown to regulate the 
maturation and expression of miRNAs in cancers [25, 
26]. We recently reported that mutp53 could 
modulate the expression of miRNAs, such as 
miR-128b-5p and miR-223 [27, 28]. Furthermore, we 
identified TP53 mutation-associated miR-205-5p to be 
the best predictor of clinical outcome in HNSCC 
patients [11]. Recent genomic data have revealed that 
mutation of TP53 is the most frequent event in 
HNSCC, occurring in up to 85% of human 
papillomavirus (HPV)-negative primary tumors [29, 
30]. Also, TP53 mutations are associated with poor 
therapeutic response and decreased survival in 
HNSCC (http://www-p53.iarc.fr) [31, 32]. 
It has been reported that miR-205 may act either 
as a tumour suppressor by inhibiting proliferation 
and invasion, or as an oncomir facilitating tumor 
initiation and proliferation, depending on the specific 
tumor context and target genes [33, 34]. High 
expression of miR-205 has been associated with tumor 
progression in HNSCC, ovarian cancer, and lung 
cancer [35-37].  
Herein, we studied the oncogenic role of 
lncMIR205HG and the transcriptional regulation of 
both hsa-miR-205-5p and its host gene in HNSCC. 
Mechanistically, we showed that mutp53 binds to the 
MIR205HG gene promoter and positively regulates its 
transcription. Two pools of biologically independent 
RNAs, lncMIR205HG and miR-205-5p, are formed by 
processing of MIR205HG pre-mRNA. We have also 
shown in HNSCC patients that high expression levels 
of lncMIR205HG are associated with tumoral samples 
and they depend upon the expression of mutp53 
proteins. 
We have previously reported that YAP1, the 
effector of the HIPPO pathway, physically interacts 
with mutp53, potentiating the transcriptional activity 
of the mutant p53/NF-Y oncogenic complex on ccna, 
ccnb1, and cdk1 gene promoters, and causes a dramatic 
increase in proliferation [9]. In this study, we show 
that MIR205HG acts as an endogenous sponge for 
miR-590-3p activity, leading to high CCNB1, Cdk1 
and YAP1 protein expression levels and increased 
proliferation. 
Results 
NF-Y and E2F1 mediate recruitment of 
mutant p53 to the MIR205HG promoter and 
upregulate the expression of lncMIR205HG 
and miR-205-5p. 
We previously reported that TP53 mutations are 
associated with a shorter recurrence-free survival in a 
cohort of HNSCC patients [11]. Tumors with 
wild-type TP53 could be discriminated from those 
carrying the mutated gene, with miR-205-5p serving 
as the best predictor of clinical outcome in HNSCC 
patients [11]. We also observed that the hsa-miR-205 
was located at the boundary of the third intron and 
the fourth exon of the MIR205 host gene (MIR205HG; 
ID: 642587: non-protein coding), which codes for the 
lncRNA (Figure 1A). Transient depletion of mutp53 
protein in CAL27 (mutp53H193L) and FaDu 
(mutp53R248L) HNSCC cell lines (Figure S1A) 
significantly decreased miR-205-5p expression (Figure 
1B). Similar findings were observed in CAL27 cells 
whose mutp53 expression was stably blocked (Figure 
S1B, C). On the other hand, the ectopic expression of 
five mutant p53 proteins among the most frequently 
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mutated p53 proteins in HNSCC (http://p53.iarc.fr), 
mutp53R273H (DNA contact mutant), mutp53R175H 
(conformational mutant), mutp53H179R 
(conformational mutant), mutp53R248W (DNA 
contact mutant) and mutp53D281G (DNA contact 
mutant) in A254 p53-null cells, resulted in significant 
upregulation of miR-205-5p expression (Figure S1D). 
Similarly, we observed downregulation of MIR205HG 
transcript in CAL27 and FaDu cell lines upon mutp53 
depletion (Figure 1C and Figure S1B, C) whereas 
ectopic expression of mutp53 in A254 cells enhanced 
MIR205HG mRNA level as evaluated by two different 
pairs of primers in the RT-qPCR analysis (Figure S1E). 
It has been demonstrated that mutant p53 
proteins physically interact with NF-Y and E2F1 
transcription factors and that this interaction occurs, 
respectively, on the CCAAT and E2F consensus 
sequences of gene promoters (ccna, ccnb, cdc25c, cdk1 
and id4) leading to increased protein expression [5, 6, 
9, 38]. Therefore, we evaluated the potential 
recruitment of mutp53 onto the regulatory elements 
located in the upstream region of the first exon of 
MIR205HG and the third intron preceding miR-205- 
5p (Figure 1D). By using MatInspector software 
(www.genomatix.de), we identified the CCAAT and 
E2F1 consensus sequences potentially involved in the 
recruitment of mutp53 protein (Figure 1D). 
Chromatin immunoprecipitation analyses (ChIP) 
of si-GFP CAL27 cells revealed that mutp53 and 
polymerase II were recruited to the CCAAT box 
(-1762bp; Figure 1E) and the E2F1 consensus sequence 
(-393bp; Figure 1F). This recruitment was impaired in 
si-p53 CAL27 cells (Figure 1E, F) and correlated with 
pan-acetylation of histone H4 and lysine 5 acetylation 
of histone H4 (Figure 1F), which were significantly 
decreased following mutant p53 depletion. 
Accordingly, miR-205-5p and MIR205HG expressions 
were significantly reduced in si-p53 CAL27 cells 
(Figure 1B, C).  
It has previously been shown that wild-type p53 
binds to the region in the third intron immediately 
upstream of miR-205-5p (Figure 1D) [39]. Indeed, a 
consensus site for wt-p53 is present in this intron. As 
expected, endogenous mutp53 protein in CAL27 cells 
was unable to bind to the wt-p53 consensus (Figure 
1E). Thus, this region served as an internal negative 
control for mutp53 chromatin enrichment. Also, the 
CCAAT box present in the MIR205HG third intron 
did not show significant mutp53 enrichment, 
suggesting that this genomic region is not responsible 
for mutp53-dependent regulation of miR-205-5p 
(Figure 1E). Wild-type p53 protein could bind to its 
p53-consensus sequence in the third intron to induce 
the transcription of miR-205 [39]. 
Since wild-type p53-carrying HNSCC cell lines 
are not available, endogenous mutp53 was knocked 
down by si-RNA transfection in CAL27 cells for 24 h 
and subsequently replaced by transfecting ectopic 
wild type p53 for an additional 24 h (Figure S1F). As 
expected, the silencing of endogenous mutp53 
decreased lncMIR205HG expression, while the 
reintroduction of wt-p53 protein did not affect it 
(Figure S1G). This result suggested that the 
MIR205HG transcription was regulated by mutant 
p53. Interestingly, analysis of ChIP-seq raw data 
generated by Vaughan and colleagues, who mapped 
the recruitment of ectopic mutp53R273H protein on 
the genome of H1299 p53 null cells, revealed 
enrichment on the MIR205HG promoter (Figure S2A) 
[40]. Further analysis of the same ChIP-seq dataset 
showed that the region immediately upstream of 
miR-205-5p in the third intron was devoid of mutp53 
binding, which was consistent with our chromatin 
immunoprecipitation results (Figure S2A and Figure 
1E). 
Given that mutp53 requires a physical 
interaction with NF-Y and E2F1 proteins on their 
respective consensus sequences to transcribe target 
genes [5, 6, 9, 38], we examined whether mutp53 
recruitment on MIR205HG promoter was dependent 
on NF-Y and E2F1 transcription factors. We found 
that depletion of NF-Y expression by siRNA 
transfection caused a strong reduction of mutp53 
occupancy on CCAAT box (Figure 1G) accompanied 
by a significant decrease in MIR205HG expression 
(Figure 1H). We previously demonstrated that 
mutp53/NF-Y interaction on the CCAAT boxes led to 
increased transcription of cell cycle regulatory genes 
(ccna, ccnb, cdc25C, and cdk1) and to high proliferation 
rates in cancer cells [5, 9]. Accordingly, we found 
reduced mRNA levels of cyclinB and cdk1 genes after 
NF-Y depletion (Figure 1H).  
MIR205HG expression also decreased upon E2F1 
depletion by siRNA transfection (Figure 1I and Figure 
S2B). As the negative control, we examined the 
recruitment of the transcription factor ZEB, which did 
not have consensus sequences on the MIR205HG gene 
promoter, by MatInspector analysis. Accordingly, we 
observed that ZEB down-regulation by specific 
si-RNA transfection did not affect MIR205HG mRNA 
expression in CAL27 cells (Figure S2C). These results 
suggested that both NF-Y and E2F1 transcription 
factors were crucial mediators of the aberrant 
MIR205HG gene expression driven by mutp53. 
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Figure 1. NF-Y and E2F1 transcription factors mediate the recruitment of mutant p53 on the MIR205HG promoter and upregulate the expression of 
both lncMIR205HG and miR-205-5p. (A) Schematic representation of the MIR205HG locus gene (Chr. 1, NC_000001.11; ID: 642587) and the position of miR-205 (miRbase 
accession: MI0000285) at the junction of the third intron and the fourth exon of the gene. (B) miR-205-5p expression was analyzed by Taq-Man assay in RNA samples derived 
from CAL27 (mutp53H193L) and FaDu (mutp53R248L) cells transfected with si-GFP oligos and two different si-RNAs against p53, si-p53#1 and si-p53#2. The expression was 
normalized versus RNU49. p-values were calculated with two-tailed Student's t-test. Statistically significant results are indicated with *p-value < 0.005 and **p-value < 0.05. (C) 
MIR205HG expression was analyzed by RT-qPCR in cDNA derived from CAL27 and FaDu cells described in (B). Statistically significant results are indicated with *p-value < 0.005 
and **p-value < 0.05. (D) Schematic representation of the MIR205HG gene promoter and the third intron. (E, F) Western blotting panel: immunoblotting of p53 and GAPDH 
(loading control) proteins from whole protein lysates of CAL27 cells transfected with si-GFP and si-p53#1 oligos. For convenience, si-p53#1 oligonucleotides are called si-p53. 
The cross-linked chromatin purified by these cells was used in ChIP experiments. A representative image is shown. ChIP analysis of mutp53, DNA Polimerase II (PolII) (E), and 
H4 acetylated histone- (H4) and H4 Lys5acetylated histone- (H4AcK5) (F) enrichments from CAL27 cells transfected with si-p53 or si-GFP as a negative control. The experiment 
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was performed in biological triplicate. The MIR205HG promoter and the third intron occupancy were analyzed by qPCR. Normalization was performed to the amount of input 
chromatin. The ChIP samples were further tested by qPCR of a region that was negative for mutp53 recruitment [66]. In all experiments, bars represent mean ± SD from three 
biological replicates. p-values were calculated with two‐tailed Student's t‐test. Statistically significant results are indicated with *p-value < 0.05. (G) ChIP analysis of mutp53 from 
CAL27 cells transfected with a commercial smart pool of siRNA oligos targeting NF-Y (si-NF-Y) or si-GFP as a negative control. The experiment was performed in biological 
triplicate. The MIR205HG promoter was analyzed by qPCR. Normalization was performed to the amount of input chromatin. p-values were calculated with two-tailed Student's 
t-test. Statistically significant results are indicated with *p-value < 10-4. (H) MIR205HG, ccnb and cdk1 gene expressions were analyzed by RT-qPCR in CAL27 cells described in (G). 
Bars represent mean ± SD from three biological replicates. p-values were calculated with two-tailed t-test. Significant p-values are indicated as *p-value < 0.05 and **p-value < 
0.01. (I) MIR205HG expression was analyzed by RT-qPCR ins CAL27 cells transfected with siGFP and two different siRNAs against E2F1 transcript, si-E2F1#1 and si-E2F1#2 
oligos. (J) MIR205HG and pre-miR-205-5p expression were analyzed by RT-qPCR from CAL27 and FaDu cells transfected with ASO-control and ASO-MIR205HG oligos. (K) 
pre-miR-205 and MIR205HG expressions were analyzed by RT-qPCR in CAL27 and FaDu cells transfected with LNA-control and LNA-miR205 oligos. In all experiments, bars 
represent mean ± SD from three biological replicates. p-values were calculated with two-tailed t-test. Significant p-values are indicated as *p-value < 0.05. 
 
To investigate the relationship between 
MIR205HG and miR-205-5p mature transcripts, we 
engineered the down-regulation of MIR205HG 
expression using highly potent single-stranded 
antisense oligonucleotides (ASO) for silencing 
lncRNAs. The results indicated that ASO-MIR205HG 
transfection in CAL27 and FaDu cells significantly 
decreased MIR205HG expression (Figure 1J). 
Interestingly, in these cells, we ascertained that 
silencing of MIR205HG did not affect miR-205-5p 
expression (Figure 1J). As further controls, before the 
splicing process, we designed two pairs of primers 
encompassing the sequence at the first exon 
(pre-MIR205HG#1 primers), and the sequence at the 
first exon and first intron junction (pre-MIR205HG#2 
primers) to amplify the mRNA precursor of 
MIR205HG (pre-MIR205HG (Figure S2D and Table 
S1). In CAL27 cells transfected with ASO-MIR205HG, 
we did not observe a decrease in pre-MIR205HG 
mRNA compared to the control (Figure S2D), 
indicating the specificity of the ASO-MIR205HG 
oligonucleotide for the mature MIR205HG transcript 
and the independence between lncMIR205HG and 
miR-205-5p mature RNA products. 
We also transfected CAL27 and FaDu cells with 
an LNA-modified 8-mer seed-targeting anti-miR-205- 
5p to obtain an efficient knock-down of miR-205-5p 
expression (Figure 1K). Silencing of miR-205-5p did 
not influence lncMIR205HG expression (Figure 1K). 
This intriguing result led us to hypothesize that 
mutp53 induces the transcription of a unique pool of 
immature mRNAs that are processed in two different 
and independent mature RNAs, lncMIR205HG and 
miR-205-5p.  
LncMIR205HG is required for pro-tumorigenic 
activities of the mutant p53 protein. 
Has-miR-205 has been shown to serve as a 
prognostic and diagnostic biomarker in various 
squamous cell carcinomas [35, 41, 42]. However, not 
much is known about the tissue expression and 
biological functions of its host gene, lncMIR205HG. 
To provide a more detailed molecular 
characterization of lncMIR205HG, we analyzed its 
expression levels and histone modification data in 
eight HNSCC cell lines [43]. We found that 
MIR205HG was expressed at high levels (FPKM > 
100) in 6 out of 8 HNSCC cell lines (Figure 2A).  
ChIP-seq data on CAL27 showed enrichment of 
H3K27ac and H3K4me3 on the MIR205HG locus 
(Figure S3A, red graphs), suggesting efficient 
transcriptional activity [44]. The histone modification 
profiles on 7 ENCODE cell lines confirmed similar 
patterns on the NHEK cell lines (Keratinocytes) 
(Figure S3A, pink graphs). Furthermore, repressive 
marker H3K27me3 was absent from the locus (Figure 
S3A). The same tracks were observed for CCNB1 
locus, which was actively transcribed in cancer cell 
lines showing high expression and a similar histone 
modification pattern (Figure S3B). In parallel, we 
performed Northern blotting on RNAs isolated from 
FaDu cells and ASO-MIR205HG and ASO-control 
CAL27 cell lines. As shown in Figure 2B, one 
transcript of approximately 900 nucleotides was 
detected by a specific pool of biotinylated probes 
(Table S3), which matched the length of the 
lncMIR205HG gene transcripts (899 nt; NR_145437.1). 
The Northern blot of CAL27 cells showed 
downregulation of the band corresponding to the size 
of the lncMIR205HG transcript of 899nt (Figure 2B). 
We confirmed the quantitative ratio of MIR205HG 
mRNA between CAL27 and FaDu cells by RT-qPCR 
(Figure 3C). 
To study the cellular localization of MIR205HG, 
we performed fractionation of nuclear and 
cytoplasmic RNAs and proteins from CAL27 and 
FaDu cells (Figure 2C). The RT-qPCR analysis 
revealed that MIR205HG transcript was localized 
mainly in the nucleus with a minor fraction residing 
in the cytosol in both cell lines (Figure 2C). These 
results were further confirmed by mRNA detection 
using Stellaris FISH technology where a probe set of 
27 multiple singly-labelled oligonucleotides 
hybridized along each MIR205HG molecule (Figure 
2D and Table S4). The signal was only detectable 
when numerous probes were bound, thereby strongly 
reducing the number of false positives.  
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Figure 2. LncMIR205HG is required for pro-tumorigenic activities of mutant p53 protein. (A) UCSC Genome Browser screenshots for MIR205HG locus. The 
displayed track shows RNA-seq expression level in 8 different HNSCC cell lines (GSE68872). (B) Total RNA was isolated from FaDu and ASO-contr and ASO-MIR205HG 
CAL27 cells, respectively. 6 μg of RNA was subjected to Northern blot using MIR205HG biotin-labelled oligos (Table S3). Ethidium bromide staining of 28S rRNA and 18S rRNA 
is shown as a loading control. (C) Fractionation of nuclei (N) and cytosol (C) from CAL27 and FaDu cells. Control of fractions was monitored by Western blot using anti-nucleolin 
and anti-actin as markers of nucleus and cytosol, respectively. MIR205HG expression was analyzed by RT-qPCR from nuclei (RNU49 expression was used to normalize) and 
cytosol (actin expression was used to normalize) fractions. The experiment conducted in two biological replicates obtained the same results. (D) FISH analysis was performed 
on CAL27 and FaDu cells with Stellaris FISH technology where a probe set of 27 multiple singly labelled oligonucleotides hybridize along each MIR205HG molecule and the signal 
is only detectable when tens of probes are bound (red). The DNA was stained with TO-PRO-3 (Blu). Representative images are shown. (E) MIR205HG and miR-205-5p 
expression was analyzed by RT-qPCR from CAL27 cells transfected with ASO-control and ASO-MIR205HG oligos. Bars represent mean ± SD from three biological replicates. 
p-values were calculated with two-tailed t-test. Significant p-values are indicated as *p-value < 0.05 versus the control sample. (F) CAL27 cells transfected for 48 h with 
ASO-control and ASO-MIR205HG oligos were labelled with PI staining solution and analyzed by flow cytometry (pre-G1, G0/G1, S, and G2/M). Experiments performed in 
triplicate yielded similar results. Statistical analysis of the number of cells (%) in G1, S and G2 phases is shown. Data are presented as mean ± SD of three independent tests. 
*p-value < 0.05. (G) Cells treated as in (E) were incubated with BrdU for 20 min. The BrdU-positive cells were then identified by immunofluorescence staining and observed 
under a fluorescence microscope. Data are expressed as the mean of the percentage of BrdU-positive cells ± SD. *p-value < 0.05. (H) MIR205HG and CCNB1 expressions were 
analyzed by RT-qPCR in cDNA derived from the H1299 clone 41 cell induced by ponasterone A (Pon+) to express mutp53R175H protein; H1299 clone 41 cell not induced 
(Pon-) was used as control. Data are presented as mean ± SD of three independent experiments. *p-value < 0.05, **p-value < 10-4. (I) and (J) The abundances of CCNB1 (I) and 
lncMIR205HG (J) transcripts in the polysome and non-polysome fractions from Pon- and Pon+ H1299 clone 41 cells were measured by RT-qPCR and normalized by total CCNB1 
and lncMIR205HG mRNAs, respectively, in all fractions. Bars represent mean ± SD from 3 replicates; a representative experiment is shown.  
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We next investigated the potential involvement 
of MIR205HG in pro-tumorigenic activities, 
considered to be a hallmark of mutp53 proteins, such 
as increased cell proliferation, colony formation 
ability, and cell motility [3, 7]. Toward this end, we 
depleted MIR205HG expression using ASOs and a 
scrambled sequence as the control in CAL27 and 
FaDu cells (Figure 2E and Figure S4A). The 
cytofluorimetric analysis performed after 48 h of 
ASO-MIR205HG and ASO-control transfection 
revealed G2-M phase cell accumulation (Figure 2F 
and Figure S4B). We employed the BrdU 
incorporation assay using the same experimental 
conditions to further investigate the significant 
increase of S phase in CAL27 cells (Figure 2F). The 
ASO-MIR205HG transfection caused a reduction of 
BrdU incorporation, thus leading to a lengthening of S 
phase (Figure 2G and Figure S4C). The reduced 
proliferation of MIR205HG-depleted cells compared 
to control cells was evaluated by MTT assay 
performed at the same time point (Figure S4D, E).  
Finally, to confirm that MIR205HG had no 
coding potential and did not associate with the 
translational machinery, ribosome- and polysome- 
associated cell fractions were isolated. We evaluated 
the distribution of lncMIR205HG transcript and the 
CCNB1 mRNA as a control in fractions with different 
translational rates in mutant p53R175H-ponasteron- 
inducible H1299 clone 41 cells [6]. As expected, we 
observed the upregulation of both MIR205HG and 
CCNB1 expression in the total mRNA samples 
prepared from these cells after induction (Pon+) of 
mutp53R175H (Figure 2H). However, compared to 
the non-induced counterparts (Pon-), a reproducible 
increase of CCNB1 mRNA level in the polysomal, 
actively translating fractions was seen upon induction 
with mutant p53 (Pon+) (Figure 2I). On the other 
hand, the MIR205HG transcript was not associated 
with the polysomal fractions in both H1299 cells with 
or without induction, thus validating MIR205HG as a 
lncRNA (Figure 2J).  
LncMIR205HG is involved in colony formation 
and migration of HNSCC cells. 
It is well established that the in vitro GOF 
activities of mutp53 are manifested in the increased 
colony-forming ability and cell motility [45]. In this 
context, we found that MIR205HG depletion caused 
significant morphological changes in both CAL27 and 
FaDu cell lines, which included tight clumping of cells 
with the cobblestone-like appearance of the epithelial 
cell phenotype (Figure 3A). To further address this 
morphological change, we first monitored the 
concentration of cellular ATP over 72 h as an 
indication of the metabolic activity. Both CAL27 and 
FaDu cells depleted of MIR205HG were metabolically 
much less active 24 h after the transfection than the 
control cells during that time (Figure 3B). In parallel, 
we monitored the dynamic mass redistribution 
(DMR) of these cells by measuring the wavelength 
shift. This label-free analysis showed that MIR205HG 
inhibition caused full repression of DMR in both cell 
lines (Figure 3C). 
We also observed that depletion of MIR205HG 
severely impaired the formation of colonies of CAL27 
and FaDu cells (Figure 3D). To further examine the 
impact of MIR205HG on cell growth, we evaluated 
the expression of cell cycle checkpoints regulatory 
proteins. Down-regulation of MIR205HG caused 
decreased expression of CCNB1 and Cdk1 proteins, 
components of the mitotic complex regulating G2/M 
transition (Figure 3E). Interestingly, we previously 
reported the important role of mutant p53 in CCNB1- 
and Cdk1-positive transcriptional regulation [5, 9]. As 
a control, we checked the expression of CCNA and 
CCNE, two cyclins involved in the regulation of G1/S 
phase, which were not modulated (Figure 3F).  
The role of MIR205HG in cell motility was 
studied by performing an in vitro transwell invasion 
assay in CAL27 and FaDu cells. As shown in Figure 
3G, H, depletion of MIR205HG expression decreased 
migration of both cell lines. Taken together, these 
findings show that lncMIR205HG probably mediates 
the oncogenic properties exerted by GOF mutp53 
proteins. 
TP53 mutations are associated with high 
expression of lncMIR205HG in HNSCC 
patients.  
Based on the above results, we hypothesized that 
expression of MIR205HG in HNSCC might be higher 
in tumoral than in non-tumoral tissues. To test this 
hypothesis, we compared its expression in tumoral 
and non-tumoral HNSCC tissue samples using our 
collection at the Regina Elena Cancer Institute and the 
Cancer Genome Atlas Data Portal (TCGA). In the first 
phase of our exploratory analysis, we hypothesized 
that TP53 status might affect the expression of 
MIR205HG. To test this hypothesis, we randomly 
selected 63 HNSCC from the 121 tissues samples 
collected at the Regina Elena National Cancer 
Institute of Rome described in our previous 
publication [11]. Out of the 63 tumor samples, 32 had 
TP53 missense mutations while 31 had wild-type 
TP53 (tumor and normal matched tissues for each 
patient) (Table S5). In the original study, we had 
observed that among the 121 patients those who 
carried TP53 mutations in the tumor exhibited a 
shorter recurrence-free survival (RFS) than those with 
wt-p53 protein [11].  
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Figure 3. LncMIR205HG is involved in colony formation and migration of HNSCC cells. (A) Effect of MIR205HG depletion on cell morphology. CAL27 and FaDu 
cells were transfected with ASO-MIR205HG and ASO-control and cell morphology was observed and photographed by phase contrast microscopy (Scale bars, 100 υm). (B) 
Label-free assay in CAL27 and FaDu cells transiently transfected with ASO-MIR205HG or ASO-control at the indicate time points. ATP amount was expressed as relative light 
units (RLU). Values are mean ± SD obtained from 2 separate experiments in quintuplicate. p-values were calculated with two-tailed t-test. Significant p-values are indicated as 
*p-value < 0.01 versus the control sample. (C) DMR label-free assay in cells treated as in (B). The change in impedance (pm) of CAL27 and FaDu cells is represented by the graph. 
Values are mean ± SD obtained from 2 separate experiments in quintuplicate. p-values were calculated with two-tailed t-test. Significant p-values are indicated as *p-value < 0.01 
versus the control sample. (D) Colony formation assay was performed in CAL27 and FaDu cells transfected with ASO-control and ASO-MIR205HG. The data was obtained by 
analysing the colonies with ImageJ software. (E) Western blot analysis performed in CAL27 and FaDu cells for CCNB1, Cdk1, CCNA, CCNE and GAPDH (loading control) 
protein expression in lysates from ASO-control and ASO-MIR205HG. (F) Representative images from the transwell migration assay by Boyden chamber in CAL27 and FaDu cells. 
Magnification, 400x. (G) Data represent the mean ± SD from three biological replicates of the transwell migration assay, each point repeated in technical quadruplicates. p-values 
were calculated with two-tailed t-test. 
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In the present study, we confirmed by RT-qPCR 
analysis that MIR205HG was upregulated in tumor 
tissues compared with matched non-tumoral tissues 
(Figure 4A). Interestingly, there was a significant 
upregulation of MIR205HG in the mutp53-carrying 
tumors (Figure 4B) compared with the group of 
wt-p53 samples (Figure 4C). 
The preferential association of MIR205HG 
expression with the mutp53-carrying samples was 
further confirmed in the HNSCC TCGA (Figure 4D, 
E). Indeed, we found increased expression of 
MIR205HG in tumoral compared to non-tumoral 
tissues (Figure 4D). We also evidenced that the 
expression of MIR205HG was significantly higher in 
samples carrying TP53 mutations when compared 
with those with intact TP53 (Figure 4E). Furthermore, 
expression of lncMIR205HG and miR-205-5p, both 
derived from a unique pre-mRNA (Figure S2D), were 
highly correlated in the group of 478 HNSCC samples 
(correlation coefficient R=0.67; p-value=10-60). This 
significant correlation indicates that MIR205HG and 
miR-205-5p transcripts are highly co-expressed in the 
HNSCC tissues. 
To further validate the analysis performed in 
TGCA subgroups, we considered PDGFRB as a gene 
transcriptionally regulated by mutant p53 [46] and 
MDM2 as a bona-fide target of wild-type p53. As 
expected, the analysis performed on the HNSCC 
TCGA database highlighted that PDGFR expression 
was significantly associated with mutant p53 samples 
(p=6.7×10-10) and MDM2 expression was significantly 
associated with wild-type p53 samples (p=2.1×10-13) 
(Figure S4F, G). Taken together, these findings 
provide clinical relevance to the in vitro data and 
suggest that lncMIR205HG, together with miR-205- 
5p, could be relevant effectors in the pro-oncogenic 
GOF of the mutp53 protein (Figure 4G). 
LncMIR205HG acts as a natural decoy for 
miR-590-3p, leading to elevated expression of 
Cyclin B and Cdk1 proteins. 
Emerging evidence highlights that lncRNAs 
elicit post-transcriptional actions by competing or 
cooperating with RNA-binding proteins, microRNAs, 
and likely other lncRNAs [12, 13]. We explored 
diverse putative biological functions of 
lncMIR205HG, including the possibility that 
MIR205HG could act as the “competing endogenous” 
RNA using specific miRNA target sites to 
post-transcriptionally modulate gene expression, as 
was previously described [47, 48].  
Bioinformatics analysis of miRNA recognition 
sequences on MIR205HG revealed the presence of a 
putative sequence for miR-590-3p binding (Figure 5A 
and Figure S5A). Initially, we used Northern blotting 
to confirm the presence of a mature miR-590-3p in the 
small RNAs-purified fraction of CAL27 cells (Figure 
S5B). We employed mimic 590-3p and mimic 205-5p 
as positive and negative controls, respectively (Figure 
S5B). Furthermore, we analysed data from a micro- 
RNA sequencing (NGS technology) performed in 
CAL27 cells present in our laboratory. The analysis 
provided a further proof of mir-590-5p expression in 
CAL27 cells (RPM>5, Figure S5C). 
Among the transcripts related to miR-590-3p, 
ccnb1 and cdk1 mRNAs were of interest for our study 
[47, 48]. The location of ccnb1 and cdk1 mRNAs, 
containing target recognition sequences for 
miR-590-3p, are shown in Figure 5B. We tested the 
hypothesis that MIR205HG, by depleting miR-590-3p, 
sustains elevated endogenous levels of ccnb1 and cdk1 
mRNAs (Figure 5C). To this end, using mimic 
oligonucleotides, we first overexpressed miR-590-3p 
in CAL27 and FaDu cells to bypass the decoy effect of 
MIR205HG on endogenous miR-590-3p (Figure 5D 
and Figure S5D). Overexpression of miR-590-3p 
mimic resulted in a marked decrease of CCNB1 and 
Cdk1 protein expression with the concomitant 
up-regulation of p21 protein (Figure 5D and Figure 
S5D). We verified that miR-590-3p mimic transfection 
did not affect lncMIR205HG, ccnb1 or cdk1 transcript 
levels, indicating that it acts through a canonical 
RNA-induced silencing complex (RISC) pathway, 
where there is a direct interaction between the 
miRNA and its ccnb1 and cdk1 mRNA targets (Figure 
5E and Figure S5E).  
We next explored whether miR-590-3p was 
effectively bound by MIR205HG. To test this, we 
recovered all MIR205HG-associated RNAs through 
ChIRP assay (chromatin isolation by RNA 
purification) by using a pool of biotinylated 
antisense-oligos for theMIR205HG mRNA sequence 
in CAL27 cells. Antisense oligos for LacZ mRNA 
sequence were used as a control. As displayed in 
Figure 5F, miR-590-3p was significantly enriched in 
the MIR205HG RNA-precipitated samples compared 
to the LacZ control. The specificity of MIR205HG 
precipitation by biotinylated tiling antisense-oligos is 
shown in Figure S5F. 
Down-regulation of MIR205HG by ASO 
transfection was expected to increase in free 
miR-590-3p. Surprisingly, it caused not only a 
decrease of CCNB1 and Cdk1 protein expression but 
also of ccnb1 and cdk1 transcription (Figure 5G, H), 
which was contrary to the observation following 
transfection with mimic miR-590-3p (Figure 5E and 
Figure S3C). This suggests the existence of additional 
regulatory mechanisms to regulate the expression of 
CCNB1 and Cdk1 through yet unexplored networks 
of biological activities of lncMIR205HG.  
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Figure 4. TP53 mutations are associated with high expression of lncMIR205HG in HNSCC patients. (A) Box-plot analysis representing the association of 
MIR205HG expression levels with the tumoral and normal tissues from the HNSCC cohort of Regina Elena National Cancer Institute of Rome (I.R.E.). The expression of 
MIR205HG was measured by RT-qPCR in cDNA obtained from each normal and tumoral matched tissues and analyzed in association with the tumoral and normal tissues. The 
63 matched samples are composed of tumors carrying missense mutations in TP53 (mutp53 n=32) and tumors with wild-type TP53 (WTp53 n=31). (B, C) RT-qPCR in cDNA 
obtained from each normal and tumoral matched tissues and analyzed in the sub-group of HNSCC patients carrying missense mutations in the TP53 gene (B) and in the sub-group 
of HNSCC patients with wild type TP53 gene (C). (D) Box-plot analysis representing the association of MIR205HG expression level with the tumoral and normal tissues from 
HNSCC by TCGA. 522 total patients: 478 tumoral and 44 normal samples. (E) Box-plot analysis representing the association of MIR205HG expression levels within the following 
sub-groups of 42 matched samples from TCGA: mutant p53, tumors carrying mutations in TP53 (n=31); wt p53, tumors with wild-type TP53 (n=11). (G) Schematic model 
representing the two ncRNA products (lncRNA and micro-RNA) derived from the positive regulation of mutant p53 protein on the MIR205HG locus gene. 
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Figure 5. LncMIR205HG acts as a natural decoy for miR-590-3p, leading to elevated expression of Cyclin B and Cdk1 proteins. (A) Schematic representation of 
MIR205HG and miR-590-3p nucleotides involved in the RNA-RNA interaction. This model was created using Inta RNA-RNA interaction software (43). (B) Representation of 
pairing between miR-590-3p and the 3’UTR of its validated mRNA targets, ccnb1 and cdk1 mRNAs [47, 48]. (C) Hypothetical model where lncMIR205HG binds and sequesters 
miR-590-3p, allowing the production of CCNB1 and Cdk1 proteins, both involved in the increase of cell proliferation. (D) Left side: miR-590-3p expression was analyzed by 
Taq-Man assay with a specific probe on RNA derived from CAL27 cells transfected with mimic control and mimic miR-590-3p oligos. The expression was normalized versus 
RNU48. Bars represent mean ± SD from three biological replicates. P-values were calculated with two-tailed t-test. Right side: a representative immunoblotting analysis of 
CCNB1, Cdk1, p21 and GAPDH (loading control) in CAL27 cells transfected with either mimic control or mimic miR-590-3p oligos. (E) MIR205HG, ccnb1 and cdk1 expression 
was analyzed by RT-qPCR in CAL27 cells transfected with either mimic control or mimic miR-590-3p oligos. (F) ChIRP-Taqman Assay analysis of miR-590-3p reveals the 
co-precipitation with lncMIR205HG transcript in CAL27 cells. Values represent the mean fold enrichment of miR-590-3p after precipitation with specific biotinylated oligos for 
MIR205HG and LacZ transcripts (LacZ as control). Bars represent mean ± SD from three biological replicates. P-values were calculated with two-tailed t-test. (G, H) MIR205HG, 
ccnb1 and cdk1 expression was analyzed by RT-qPCR in CAL27 (G) and FaDu (H) cells transfected with either ASO-control or ASO-MIR205HG oligos. Bars represent mean ± 
SD from three biological replicates. p-values were calculated with two-tailed t-test. Significant p-values are indicated as *P-value <0.05 and **P-value <0.01  
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To address the inverse correlation between 
miR-590-3p and ccnb/cdk1 in tumors, we first 
evaluated the miR-590-3p expression in the TCGA 
dataset of HNSCC (Figure S6). Interestingly, 
miR-590-3p expression was not deregulated in 42 
tumors vs. matched normal samples (Figure S6A) nor 
in the entire tumor series (478 tumors) vs. 44 
un-matched normal tissues (Figure S6B). This 
observation supports our hypothesis that in HNSCC 
cells the regulation of miR-590-3p activity is mainly 
modulated by the MIR205HG decoy effect rather than 
by modulation of its levels. Accordingly, there was a 
significant association between high levels of 
MIR205HG and ccnb1 and cdk1 mRNAs when 
analyzed in 42 matched tumoral and non-tumoral 
samples (Figure S6C, D) and in 478 tumoral and 44 
un-matched normal tissues (Figure S6E, F). Of note, 
lncMIR205HG, ccnb1 and cdk1 were also positively 
correlated in the tumor samples series as assessed by 
computing the Pearson correlation coefficient (R) 
(Table 1). These data strongly implied that the 
MIR205HG/miR-590-3p ncRNA complex could be a 
relevant executor of the pro-oncogenic functions of 
mutant p53. 
 
Table 1. Results of Pearson correlation analysis relative to 
MIR205HG, CCNB1 and Cdk1 in 522 HNSCC samples from 
TCGA (478T). 
N° R Pearson p-value 
CCNB1/Cdk1 0.81 1.130×10-121 
MIR205HG/CCNB1 0.17 1.1×10-4 
MIR205HG/Cdk1 0.15 8.25×10-4 
 
LncMIR205HG depletes miR-590-3p and 
induces high levels of YAP protein. 
Recently, we identified the transcriptional 
co-factor YAP1 (Yes-associated protein) as a partner 
of GOF mutp53 proteins in diverse types of tumors 
[9]. Amplified or hyperactivated YAP1 functions as an 
oncogene in numerous human solid tumors. It is the 
main effector of the HIPPO tumor suppressor 
pathway [49, 50]. We showed that YAP1 is an 
important cofactor for the aberrant transcriptional 
activity of the mutant p53/NF-Y oncogenic complex 
to modulate the expression of ccna, ccnb, and cdk1 
genes in cancer cells [9]. miR-590-3p did not affect the 
MIR205HG expression nor ccnb1 and cdk1 transcript 
levels, indicating that it acts through a canonical RISC 
pathway (Figure 5E). We reasoned that another 
parallel MIR205HG-driven mechanism might affect 
CCNB1 and Cdk1 expressions based upon the results 
obtained after MIR205HG depletion (Figure 5G, H). 
Therefore, we tested the hypothesis that MIR205HG 
could modulate the expression of YAP and 
consequently that of ccnb and cdk1 genes. Indeed, we 
found that the ASO-MIR205HG transfection caused a 
strong down-regulation of YAP protein expression 
but not that of other transcription factors that we 
evaluated to check the specificity (Figure 6A and 
Figure S7A). The reduction in YAP’s transcriptional 
ability in MIR205HG-depleted cells was further 
confirmed by the relative decrease of the mRNAs of 
ctgf and ankrd1, well-defined transcriptional targets of 
YAP (Figure 6B). This led us to explore whether YAP 
mRNA could be targeted by miR-590-3p and whether 
MIR205HG sponge activity for miR-590-3p could 
counteract such effect and contribute to maintaining 
high levels of YAP protein.  
To test this hypothesis, we transfected mimic 
miR-590-3p in CAL27 cells and observed the 
downregulation of YAP protein and the relative 
decrease of ctgf and ankrd1 mRNAs (Figure 6C, D). We 
obtained similar results in the FaDu cell line (Figure 
S7B, C). Furthermore, a seed-targeting sequence for 
miR-590-3p was detected in the 3'UTR of YAP mRNA, 
suggesting a direct regulation of YAP expression by 
miR-590-3p (Figure 6E). This prompted us to clone a 
285 bp of YAP-3’UTR encompassing the binding site 
for miR-590-3p downstream from the luciferase 
sequence. This vector was co-transfected with mimic 
miR-590-3p or a mimic control in the H1299 cell line. 
Luciferase assay showed that the YAP 3’UTR was 
specifically targeted by mimic-590-3p (Figure 6F). 
Since we have previously shown that human mutp53 
physically interacts with YAP and NF-Y on the 
CCAAT boxes of the promoters of cell 
cycle-regulatory genes [9], we evaluated the impact of 
miR-590-3p on mutp53/YAP/NF-Y transactivation. 
To this end, we performed luciferase assays using a 
reporter vector (pCCAAT-B2LUC), which contained 
three CCAAT boxes from the murine cyclin B2 
promoter [5, 9]. As a confirmation of the ability of 
miR-590-3p to downregulate YAP, we found that 
overexpression of mimic miR-590-3p significantly 
reduced cyclin B2 promoter activity (Figure 6G, black 
columns and Figure S7D, E). By transfecting a vector 
with three mutated CCAAT-boxes (pmutCCAAT- 
B2LUC), which could not be bound by NF-Y, we 
observed no significant modulations (Figure 6G, grey 
columns and Figure S7D, E). Notably, the concomitant 
overexpression of YAP and miR-590-3p was able to 
overcome miR-590-3p-dependent down-regulation of 
the CCNB2 promoter (Figure 6G). These results 
highlighted that miR-590-3p had a strong impact on 
the YAP/mutantp53 complex that was required to 
support NF-Y-aberrant transactivation activity in 
tumor cells.  
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Figure 6. LncMIR205HG sponges miR-590-3p and unleashes high levels of YAP protein. (A) Immunoblotting to detect YAP and GAPDH (loading control) proteins 
in whole protein extracts from CAL27 cells transfected with ASO-control and ASO-MIR205HG. Representative images are shown. (B) ctgf and ankrd1 expression was analyzed 
by RT-qPCR in CAL27 treated as in (A). (C) Immunoblotting to detect YAP and GAPDH (loading control) proteins in whole protein extracts from CAL27 cells transfected with 
mimic control and mimic miR-590-3p. Representative images are shown. (D) ctgf, ankrd1 and yap1 expression was analyzed by RT-qPCR in CAL27 treated as in (C). In all 
RT-qPCRs, bars represent mean ± SD from three biological replicates. p-values were calculated with two-tailed t-test. Significant p-values are indicated as *p-value < 0.05. (E) 
Scheme of pairing between the sequences of miR-590-3p and the 3’UTR of YAP1 transcript calculated by the rna22 bioinformatic tool (46). (F) Luciferase activity for 
YAP-3’UTR-pGL3 plasmid was determined after 24 h of transfection in H1299 cells. The results are representative of three independent experiments. Bars represent mean ± SD 
from three biological replicates. p-values were calculated with two-tailed t-test. Significant p-values are indicated. (G) CAL27 cells treated as indicated were transiently 
transfected with pCCAAT-B2LUC (100 ng) or pmutCCAAT-B2LUC (100 ng) luciferase reporter vectors. (H) Immunoblotting from whole protein extracts of A254 cells 
transfected as indicated to detect CCNB1, Cdk1, YAP, p53 and GAPDH (as loading control). Representative images are shown. (I) Western blot analysis for YAP, CCNB, Cdk1 
and GAPDH (loading control) protein expression in lysates from control (si-GFP) and p53-depleted (si-p53) CAL27 cell lines. In the lines 1 and 2, the expression vectors were 
co-transfected with mimic control. Representative images are shown. (G) Viability of the CAL27 cell line transfected as described in (J) and reported in the legend to the graph 
was determined by ATPlite luminescence analysis. ATP amount was expressed as relative light units (RLU). All the values are mean ± SD of six replicates from three independent 
experiments. (K) Schematic representation summarizing cell cycle gene regulation by mutp53 throughout the transcription of lncMIR205HG and miR-205-5p. 
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Previously, we showed that mutp53 
overexpression was able to induce CCNB2 and Cdk1 
mRNA and protein expression [5, 9]. To further 
dissect the mutp53/MIR205HG/miR-590-3p 
pathway, we expressed mutp53R175H protein in an 
A254 p53 null cell line. As expected, we observed an 
increase in CCNB1, Cdk1, and YAP mRNA and 
protein expressions compared with the control 
(Figure 6H, lines 1 and 2 and Figure S7F). Under these 
conditions, concomitant mimic miR-590-3p 
expression almost completely prevented the mutant 
p53-induced increase in CCNB1, Cdk1, and YAP 
protein levels (Figure 6H and Figure S7G). These 
results implied that, downstream of mutant p53, the 
MIR205HG sponge activity was required to eliminate 
miR-590-3p in tumor cells. The knock-down of 
mutp53 protein in different cell lines elicited the 
downregulation of CCNA, CCNB1, Cdk1, and 
Cdc25C, as the mutp53/NF-Y/YAP oncogenic 
complex modulated their mRNA transcription (Figure 
S7H) [5, 9]. Also, we observed the down-regulation of 
CCNB1, Cdk1, and YAP, both at protein and mRNA 
levels (Figure 6I and Figure S7I-K) in HNSCC cell 
lines when mutp53 was knocked down. Thus, mutp53 
could regulate the cancer cell proliferation rate by at 
least two pathways: by the direct induction of 
cell-cycle-related genes, such as CCNB1 and Cdk1, 
and by inducing the MIR205HG lncRNA, which 
sponges miR-590-3p that targets CCNB1, Cdk1, and 
YAP (Figure S7H). In turn, YAP participates in the 
mutp53/NF-Y oncogenic complex to sustain the 
cell-cycle-related gene expression, forming a 
regulatory loop [5, 9] (Figure S7H). 
We have previously described that the 
YAP/mutant p53 complex strongly enhances cancer 
cell proliferation [9]. In this study, we confirmed that 
ectopic expression of YAP increases cell proliferation 
in CAL27 cells (Figure 6J). Strikingly, the transfection 
of mimic 590-3p significantly impaired the 
proliferation rate of CAL27 cells. The concomitant 
overexpression of YAP and miR-590-3p rescued 
miR-590-3p-dependent inhibition of cell growth of 
CAL27 cells, demonstrating that miR-590-3p impacts 
the functional axis driven by YAP/mutant p53 to 
sustain proliferation of HNSCC cells (Figure 6J, K and 
Figure S7L). 
Discussion  
About 70% of the human genome is transcribed, 
but less than 2% of the genome encodes proteins. 
Noncoding RNAs (ncRNAs) can be classified as small 
(≤200 base pairs) or long ncRNAs (lncRNA, >200 base 
pairs). The human genome encodes around ten 
thousand lncRNA genes [51] and, like protein-coding 
genes, some lncRNAs can mediate oncogenesis or 
tumor suppression and are, therefore, a potential new 
class of cancer therapeutic targets [52]. Despite this 
relevance to cancer, only a small number of lncRNAs 
have been functionally characterized. 
Here, we provide insights into the oncogenic 
crosstalk between mutp53 proteins and ncRNAs. 
Missense mutations in the TP53 tumour suppressor 
gene are known to be associated with tumour 
progression, metastasis, and poor survival. In vivo 
studies have provided evidence that an oncogenic 
cellular context can activate GOF mutp53 protein [53]. 
In this study, we have shown that mutp53 is involved 
in the aberrant transcriptional up-regulation of 
miR-205-5p and MIR205HG lncRNA, contributing to 
cancer proliferation in HNSCC. Previous studies 
revealed that miR-205 might have contradictory roles 
in malignancy [35]. Experimental research work 
revealed the tumor-suppressive function of miR-205 
in prostate cancer, where miR-205 sustains epithelial 
cell phenotype by repressing genes involved mostly 
in the acquisition of invasive behaviour and 
increasing cell-to-cell adhesion [33]. On the other 
hand, miR-205-5p is a well-characterized oncomir in 
ovarian cancer and HNSCC [36, 54]. We previously 
reported that miR-205-5p belongs to a signature of 12 
miRNAs that predicts the risk of recurrence in 
HNSCCs [11]. However, the function that miR-205 
exerts in different cancer tissues depends on the 
cellular context and is specific to the tumour subtype, 
as well as its cellular origin and stage of tumor 
progression. Our in vitro studies have shown that the 
regulation of the entire MIR205HG locus 
encompassing miR-205-5p is driven by mutp53 
protein, which aberrantly induces miR-205-5p 
expression (Figure 1). 
MIR205HG is a 4173bp long (Gene ID: 642587) 
intergenic non-protein coding RNA (lncRNA). 
Pre-miR-205 resides at the boundary of the third 
intron and the fourth exon of the MIR205-host gene 
(Figure 1A, D). So far, very little, if any, evidence is 
available for any biological or molecular functions of 
lncMIR205HG in physiological or disease processes in 
humans. However, it is becoming clear that lncRNAs 
can have numerous molecular functions, including 
modulating transcriptional patterns, regulating 
protein activities, serving structural or organizational 
roles, altering RNA processing events, and serving as 
precursors to small RNAs [55]. Diverse studies have 
implicated many dysregulated lncRNAs in various 
human diseases including cancers, although it is not 
clear whether these lncRNAs are causal or 
symptomatic of the disease state [14, 52]. Several 
questions are being actively investigated such as the 
number of lncRNAs that are transcribed in mammals, 
the biological functions of lncRNAs and how 
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lncRNAs exert their effects. 
Here we report the characterization of the 
MIR205HG gene promoter and the regulation of 
lncMIR205HG expression in HNSSC bearing 
mutations in the TP53 gene. We showed that mutp53 
is recruited on specific DNA sequences of the 
MIR205HG promoter region (CCAAT and E2F1 
binding sequences) thereby augmenting the 
expression of mRNA (Figure 1). We demonstrated 
high expression of MIR205HG in tumor samples from 
TCGA and also in a cohort of HNSCC patients 
previously analyzed by our group (Figure 4A, D) [11]. 
Furthermore, we established the close correlation 
between high expression of MIR205HG in HNSCC 
tumors carrying mutations in the TP53 gene 
compared to those with wild-type TP53 (Figure 4B, C, 
E). Consistent with this, expression of MIR205HG was 
associated with pro-tumorigenic functional activities 
such as increased cell proliferation, cell motility, and 
ability to form colonies (Figure 2 and Figure 3). 
Collectively, these results suggest a model whereby 
mutp53 protein promotes the transcription of MIR205 
pre-mRNA by regulating the promoter region 
upstream of the first exon, then, the splicing process 
produces the mature lncMIR205HG and hsa-miR-205- 
5p (Figure 4G). 
Our study also focused on dissecting the 
molecular mechanisms by which lncMIR205HG 
increased proliferation in HNSCC cancer cells. 
Sequestration of ncRNA and/or proteins is a 
documented mechanism by which lncRNAs exert 
their regulatory function [56]. An in silico analysis, 
aimed at examining the functional RNA domains of 
MIR205HG, highlighted a region involved in binding 
to miR-590-3p (Figure S5A). Interestingly, Cyclin B 
and Cdk1, which are key regulators of cell cycle 
progression and are upregulated by mutant 
p53/NF-Y/YAP oncogenic complex, have also been 
reported as targets of miR-590-3p [5, 9, 47, 48]. We 
showed that high expression of MIR205HG driven by 
GOF mutp53 proteins depleted miR-590-3p and 
induced Cyclin B and Cdk1 expression, thereby 
leading to increased cell proliferation (Figure 5 and 
Figure 6). Consistent with these findings, high 
expression of MIR205HG is associated with elevated 
levels of ccnb and cdk1 in HNSCCs carrying mutated 
TP53. Furthermore, we have demonstrated here that 
YAP, which appears to be crucial for mutp53 GOF, is 
a direct target of miR-590-3p. Hence, sequestering of 
miR-590-3p by MIR205HG allows concomitant 
transcription of ccnb and cdk1 genes by YAP/mutant 
p53 complex followed by translation of the functional 
Cyclin B and Cdk1 proteins, leading to increased 
proliferation of head and neck cancer cells (Figure 6I). 
Taken together, our study attempted to decipher 
the molecular network including lncRNAs, miRNAs, 
and mRNAs whose dysregulation may have a 
significant impact on tumors carrying TP53 
mutations. Our results also have therapeutic 
implications by identifying potential new therapeutic 
targets for designing more effective drugs. 
Materials and Methods 
Cells 
Head and neck cancer CAL27 (mutp53H193L), 
FaDu (mutp53R248L), A254 (p53 null) and lung 
cancer H1299 (p53 null) cell lines were cultured in 
RPMI medium (Invitrogen, Carlsbad, CA, USA). 
H1299 clone 41 cells were cultured and induced as 
previously reported [6]. Media were supplemented 
with 10% (v/v) FBS (Invitrogen, Carlsbad, CA, USA). 
All cell lines were purchased from ATCC and were 
authenticated by STR genotyping with Promega 
PowerPlex® 1.2 system and the Applied Biosystems 
Genotyper 2.0 software for analysis of the amplicons. 
Cells were maintained in culture for no more than six 
passages. All cell lines have been tested by PCR/IF for 
Mycoplasma presence. 
Plasmids and RNA transfection 
Mutant p53 and YAP exogenous expression 
were performed using pcDNA3-p53-R175H, 
pcDNA3-p53-R273H, and pcDNA3-YAP vectors, and 
empty pcDNA3 was used as the control [9]. Cells 
were transfected with Lipofectamine 2000 following 
the manufacturer’s instructions (Invitrogen, Carlsbad, 
CA, USA). 
The following sequences were employed for 
si-RNA oligonucleotides transfection: si-p53#1 and 
si-p53#2 oligos were previously described [5, 9]; 
si-GFP employed as non-silencing control was 
5'-GGCTACGTCCAGGAGCGCACC-3' [5, 9]; si-NF- 
YB was a smart pool of three target-specific oligos 
(sc-29945 Santa Cruz Biotechnology) [9]; si-E2F1#1 
and si-E2F1#2 oligos were previously described [6]. 
To knock-down hsa-miR-205-5p and 
hsa-miR-590-3p expression, we used miRCURY 
LNATM miRNA Inhibitor purchased from Exiqon. 
These miRCURY LNATM miRNA inhibitors contained 
phosphorothioate bonds. The sequences were: 
"LNA-miR-205-5p":5'-AGACTCCGGTGGAATGAAG
G-3' (n°410131-00); "LNA-miR-590-3p":5'- ACTAGCT 
TATACATAAAATTA” (n° 4105239-001); "LNA-miR- 
control": 5'-GTGTAACACGTCTATACGCCCA-3' (n° 
199004-00).  
To overexpress hsa-miR-590-3p, we used 
CONmiR mimic purchased from Riboxx GmbH: 
mimic miR-590-3p n° M-00306-0005; mimic negative 
n° K-01001-0005. 
To down-regulate lncMIR205HG expression, we 
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used Exiqon LNA™ GapmeR antisense technology. 
The LNA™-containing flanking regions confer 
nuclease resistance to the antisense oligo while at the 
same time increase target binding affinity regardless 
of the GC content. The central DNA “gap” activates 
RNase H cleavage of the target RNA upon binding. 
Antisense oligonucleotide (ASO) was 16 nucleotides 
long containing LNA™ in the flanking regions and 
DNA in a LNA™ free central gap. We used the Exiqon 
online design tool to produce the following antisense 
oligo at the junction of two exons: ASO-MIR205HG, 
5'-GTGTCCTATATAAAGC-3'; ASO-negative control 
A supplied by Exiqon n°300610. 
RNAs were transfected with RNAiMax reagent 
following the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA, USA). 
RNA isolation, quantitative real-time PCR 
analysis 
Total RNA was extracted from cells using TRI 
Reagent (Invitrogen, ThermoFisher Scientific USA) 
according to the manufacturer’s instructions. 5 μg of 
total RNA was reverse-transcribed at 37°C for 60 min 
in the presence of random hexamers and Moloney 
murine leukemia virus reverse transcriptase 
(Invitrogen, ThermoFisher Scientific USA). The small 
RNA fraction was isolated from cultured cells using 
NucleoSpin miRNA (MACHEREY-NAGEL GmbH & 
Co.) according to the manufacturer’s instructions. 
To analyze the expression of miRs, 30 ng RNA 
was retro-transcribed using TaqMan microRNA 
Reverse Transcription Kit (Applied Biosystems) and 
real-time PCR of miR expression was carried out in a 
final volume of 10 μl using TaqMan MicroRNA® 
Assays (Applied Biosystems) and normalized using 
RNU48, RNU49 and RNU19 as endogenous controls. 
TaqMan probes for miRNAs and RNU were 
purchased from Applied Biosystems. 
PCR analyses were carried out using specific 
oligonucleotides for genes listed in Table S1. To 
analyze MIR205HG transcript (Figure S1E), we used 
both MIR205HG_1 and MIR205HG_2 pairs of primers 
in RT-qPCRs; in the figures of the manuscript only the 
experiments with the MIR205HG_1 Forward and 
Reverse primers are reported. The mRNA expression 
was measured by real-time PCR using the SYBR 
Green assay (Applied Biosystems, Carlsbad, CA, 
USA) on a StepOne instrument and 7500 Fast 
Real-Time PCR System (Applied Biosystems). All 
primer sets worked under identical quantitative PCR 
cycling conditions with similar efficiencies to obtain 
simultaneous amplification in the same run. The 2-ΔΔCT 
method for relative quantitation of gene expression 
was used to determine mRNA expression levels. 
GAPDH and beta-actin gene expression were used as 
endogenous controls to standardize mRNA 
expression. All reactions were performed in triplicate. 
p-values were calculated with two-tailed Student's 
t-test. Statistically significant results are indicated by a 
p-value < 0.05.  
Northern blotting 
To detect mature miR-590-3p, the small RNA 
fraction was separated on a denaturing 12% 
polyacrylamide gel containing 8 M urea, transferred 
to Nytran N membrane (Amersham Hybond -N+) 
and fixed by ultraviolet cross-linking. Membranes 
were probed with the LNA-biotinylated miR-590-3p 
oligonucleotide, complementary to the mature 
microRNA, the sequence of which was 5'- 
5Biosg-ACTAGCTTATACATAA-3' (IDT, Belgium). 
To study lncMIR205HG transcript, total RNA 
was separated by electrophoresis in 1% agarose gel 
containing 2% formaldehyde, followed by blotting to 
a positively charged nylon membrane (Amersham 
Hybond -N+). The blotted RNAs were fixed to the 
membrane by UV irradiation. The membrane was 
incubated with antisense biotinylated RNA probes 
whose sequences are listed in Table S3. 
Prehybridization and hybridization of the filters were 
carried out in PerfectHyb Plus Hybridization Buffer 
(Sigma, Life Science) according to the manufacturer’s 
instructions at 40°C. After hybridization, the 
membranes were washed at low stringency in 2×SSC, 
0.1% SDS at room temperature twice for 5 min and at 
high stringency in 0.5 SSC, 0.1% SDS at 40°C twice for 
5 min. The biotin-labelled probes were detected using 
streptavidin-HRP conjugate antibody (Sigma, Life 
Science). The immunodetection was performed with 
the aid of the enhanced chemiluminescence system 
(Thermo Fisher Scientific, Rockford, IL, USA). The 
acquisition of the chemiluminescence was performed 
by using Alliance 4.7 by UVITEC (Eppendorf). 
Polysome analysis 
We performed polysome purification as 
previously described [6]. For RT-qPCR, mRNA 
abundance was calculated with the delta CT method 
and normalized by total CCNB1 and MIR205HG 
mRNAs in all the fractions.  
Chromatin isolation by RNA purification 
(ChIRP) 
ChIRP was performed as described by Chu and 
colleagues [57]. Briefly, cells were cross-linked for 10 
min with 1% glutaraldehyde at room temperature, 
and the reaction was quenched with 10% volume of 
1.25 M glycine at room temperature for 5 min. 
To prepare chromatin, cells were resuspended in 
Swelling Buffer (0.1 M Tris pH 7.0, 10 mM KOAc, 15 
mM MgOAc) supplemented with 1% NP-40, 1 mM 
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DTT, 1 mM PMSF, complete protease inhibitor, and 
0.1 U/μL Superase-in (Ambion) for 10 min on ice. The 
cell suspension was then dounced and pelleted at 
2500 × g for 5 min. Nuclei were further lysed in 
nuclear lysis buffer (50 mM Tris 7.0, 10 mM EDTA, 1% 
SDS, 1mM DTT, PMSF, P.I., and Superase-in) on ice 
for 10 min, and sonicated using Bioruptor 
(Diagenode) until most chromatin had solubilized 
and DNA was in the size range of 100-500 bp. 
Chromatin was diluted in 2 times volume of 
hybridization buffer (500 mM NaCl, 1% SDS, 100 mM 
Tris 7.0, 10 mM EDTA, 15% formamide, with DTT, 
PMSF, P.I, and Superase-in freshly added). 100 pmol 
probes was added to 3 mL of diluted chromatin, 
which was mixed by end-to-end rotation at 37°C for 4 
h. Streptavidin-magnetic C1 beads were blocked with 
1 mg/mL BSA for 1 h at room temperature and 
washed three times with nuclear lysis buffer. 
Beads:biotin-probes:RNA:chromatin adducts were 
captured by magnets (Invitrogen) and washed five 
times with 40× beads volume of wash buffer (2× SSC, 
0.5% SDS, with DTT and PMSF freshly added). After 
the last wash buffer was removed, beads were 
resuspended in 10× original volume of RNA pK 
buffer (100 mM NaCl, 10 mM Tris 7.0, 1 mM EDTA, 
0.5% SDS) and 0.2 U/μL Proteinase K (Invitrogen). pK 
treatment was carried out at 65°C for 45 min, followed 
by boiling for 15 min, and trizol:chloroform 
extraction. Eluted RNA was subjected to quantitative 
reverse-transcription PCR (qRT-PCR) for the 
detection of enriched transcripts. 10 oligonucleotides 
against MIR205HG mRNA and 2 against LacZ as the 
control were designed using an online designer at 
www.singlemoleculefish.com. All probes were 
BiotinTEG-modified at the 3-prime end (Exiqon). 
ChIRP oligos are listed in Table S3. 
Head and neck tumour tissue samples 
The head and neck squamous cell carcinoma 
patients were previously described by Ganci and 
colleagues (Table S5) [11, 58]. Briefly, patients with 
primary HNSCC and no previous treatment with 
radiotherapy or chemotherapy who underwent 
resection in the Otolaryngology Head&Neck Surgery 
Department of Regina Elena National Cancer Institute 
in Rome were used in this study. The Scientific Ethic 
Committee of the Regina Elena National Cancer 
Institute approved the study protocol (CE/379/08). 
TP53 mutations in these samples were evaluated by 
sequencing of exons 2 through 11 of the TP53 gene. 
lncMIR205HG was analyzed by RT-qPCR in a group 
of 63 HNSCC tumor samples and their normal 
counterparts. Normal samples were collected from 
the surgery resection margin from each patient and 
were all histologically checked for the absence of 
tumor cells [11]. Normal samples were also subjected 
to TP53 sequencing and were negative for mutations. 
Bioinformatic analyses  
The mature miR sequences were taken from the 
miRBase database [59]. lncMIR205HG was displayed 
using the UCSC genome browser [60]. The likelihood 
of binding of a mature miR-590-3p to lncMIR205HG 
was evaluated using the MiRbase and MiRwalk 
packages [59, 61] and further validated using the 
Inta-RNA-interaction tool [62]. 
After evaluation of common binding sequences, 
the putative pairing sequence of miR-590-3p on 
MIR205HG was identified and is shown in Figure 
S5A. CCNB1 and Cdk1 were validated targets of 
miR-590-3p. Furthermore, we searched for their "seed 
sequence" on CCNB1 and Cdk1 mRNA using 
MiRTarbase, as shown in Figure 5A [63]. We 
confirmed this analysis also using MicroRNA.org [64] 
and rna22 packages [65]. 
ChIP-seq re-analysis 
Aligned SAM files were kindly provided by the 
authors of [40]. We converted all of them back to 
FASTQ with Picard to use our custom analysis 
pipeline from scratch. Three replicates of p53 Ab in 
the H1299 cell line were merged for downstream 
analysis. ~22 million reads were aligned with Bowtie2 
[66] and bigWig files were generated from MACS2 
[67] bedgraph enrichment track.  
RNA-Seq analysis  
RNA-Seq data were analyzed via our cloud 
pipeline of choice, RAP [68], a Tuxedo-Suite-based 
workflow. RNA-seq bigWigs were generated from 
Tophat mapping data [69]. 
Statistical analysis 
Data are presented as mean ± SD or SEM, 
derived from at least three independent experiments. 
ANOVA analysis was performed by R project tool. 
Student's t-test (two-tailed) was also conducted. A 
p-value < 0.05 was indicated as statistically 
significant.  
Abbreviations 
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